<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="34667b54-e4af-3fe6-e063-6294a90af0e1"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>Cyproheptadine Hydrochloride Oral Solution, USP, 2 mg/5 mL
 <br/>
      <br/>
Rx only
</title>
   <effectiveTime value="20250505"/>
   <setId root="996dd4c6-ebcf-42e8-a950-9d34bb6f404f"/>
   <versionNumber value="105"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="171714327"/>
            <name>Bryant Ranch Prepack</name>
            <assignedEntity>
               <assignedOrganization>
                  <id root="1.3.6.1.4.1.519.1" extension="171714327"/>
                  <name>Bryant Ranch Prepack</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="171714327"/>
                        <name>Bryant Ranch Prepack</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" displayName="repack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72162-2065" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C73607" displayName="relabel" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72162-2065" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="3466b329-d56e-6730-e063-6294a90a001a"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250505"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="72162-2065" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>CYPROHEPTADINE HYDROCHLORIDE</name>
                        <formCode code="C42986" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>CYPROHEPTADINE HYDROCHLORIDE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="70752-101" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XF417D3PSL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS CITRIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="35SW5USQ3G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>D&amp;C YELLOW NO. 10</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRISODIUM CITRATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="X045WJ989B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SORBIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="V95R5KMY2B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PEPPERMINT</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="2"/>
                              <denominator unit="mL" value="5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="NJ82J0F8QC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CYPROHEPTADINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2YHB6175DO" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CYPROHEPTADINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="473" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="72162-2065-2" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43172" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, GLASS"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20240812"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="473" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="72162-2065-4" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43172" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, GLASS"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250502"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA212423" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190522"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLFLAVOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C73408" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PEPPERMINT" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="L6b04ef1f-0906-4137-8c0a-8111e94e0eb1">
               <id root="34667b54-e49c-3fe6-e063-6294a90af0e1"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Each 5 mL (one teaspoonful) contains:</content>Cyproheptadine Hydrochloride 2 mg 
  <br/>
                     <br/>
                     <content styleCode="bold">Inactive Ingredients:</content>Citric acid, D&amp;C Yellow #10, peppermint flavor, purified water, propylene glycol, sodium citrate, sorbic acid (0.1% as preservative) and sucrose syrup.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold"> Inactive ingredients for Cyproheptadine Oral Solution (Sugar Free):</content>alcohol 5% (v/v), butylated hydroxyanisole, citric acid, D&amp;C Yellow #10, peppermint flavor, propylene glycol, purified water, sodium citrate, sorbic acid (0
 
  <content styleCode="bold">.</content>1%, as preservative), sucralose.

 </paragraph>
                  <paragraph>Cyproheptadine HCl is an antihistaminic and antiserotonergic agent. Cyproheptadine hydrochloride is a white to slightly yellowish, crystalline solid, with a molecular weight of 350.89, which is slightly soluble in water, freely soluble in methanol, sparingly soluble in ethanol, soluble in chloroform and practically insoluble in ether. It is the sesquihydrate of 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine hydrochloride. The molecular formula of the anhydrous salt is C
 
  <sub>21</sub>H
 
  <sub>21</sub>N•HCl and the structural formula of the anhydrous salt is:

 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L8dde3ea2-a610-4a36-ae9b-a659eb58912a"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240615"/>
               <component>
                  <observationMedia ID="L8dde3ea2-a610-4a36-ae9b-a659eb58912a">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="chemsture.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lbd8d9d53-8236-48ca-af60-caaaea9577a7">
               <id root="34667b54-e49d-3fe6-e063-6294a90af0e1"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Cyproheptadine is a serotonin and histamine antagonist with anticholinergic and sedative effects. Antiserotonin and antihistamine drugs appear to compete with serotonin and histamine, respectively, for receptor sites.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Pharmacokinetics and Metabolism:</content>After a single 4 mg oral dose of
 
  <sup>14</sup>C-labeled cyproheptadine HCI in normal subjects, given as tablets or syrup, 2-20% of the radioactivity was excreted in the stools. Only about 34% of the stool radioactivity was unchanged drug, corresponding to less than 5.7% of the dose. At least 40% of the administered radioactivity was excreted in the urine. No detectable amounts of unchanged drug were present in the urine of patients on chronic 12-20 mg daily doses of cyproheptadine syrup. The principal metabolite found in human urine has been identified as a quaternary ammonium glucuronide conjugate of cyproheptadine. Elimination is diminished in renal insufficiency.

 </paragraph>
               </text>
               <effectiveTime value="20240615"/>
            </section>
         </component>
         <component>
            <section ID="La8d807e3-a208-489e-b135-246eeedabd8c">
               <id root="34667b54-e49e-3fe6-e063-6294a90af0e1"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Perennial and seasonal allergic rhinitis 
  <br/>  Vasomotor rhinitis 
  <br/>  Allergic conjunctivitis due to inhalant allergens and foods 
  <br/>  Mild, uncomplicated allergic skin manifestations of urticaria and angioedema 
  <br/>  Amelioration of allergic reactions to blood or plasma 
  <br/>  Cold urticaria 
  <br/>  Dermatographism
 </paragraph>
                  <paragraph>As therapy for anaphylactic reactions
 
  <content styleCode="italics">adjunctive</content>to epinephrine and other standard measures after the acute manifestations have been controlled.

 </paragraph>
               </text>
               <effectiveTime value="20240615"/>
            </section>
         </component>
         <component>
            <section ID="L499e964f-1f95-4c88-a041-04edd8212c5b">
               <id root="34667b54-e49f-3fe6-e063-6294a90af0e1"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Newborn or Premature Infants:</content>This drug should
 
  <content styleCode="italics">not</content>be used in newborn or premature infants.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Nursing Mothers:</content>Because of the higher risk of antihistamines for infants generally and for newborns and prematures in particular, antihistamine therapy is contraindicated in nursing mothers.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Other Conditions:</content>
                     <br/>  Hypersensitivity to cyproheptadine and other drugs of similar chemical structure 
  <br/>  Monoamine oxidase inhibitor therapy (see
 
  <linkHtml href="#L2648fe94-2cb7-44da-b800-dc1a2df77465">Drug Interactions</linkHtml>) 
  <br/>  Angle-closure glaucoma 
  <br/>  Stenosing peptic ulcer 
  <br/>  Symptomatic prostatic hypertrophy 
  <br/>  Bladder neck obstruction 
  <br/>  Pyloroduodenal obstruction 
  <br/>  Elderly, debilitated patients

 </paragraph>
               </text>
               <effectiveTime value="20240615"/>
            </section>
         </component>
         <component>
            <section ID="Ld80fea9c-eafe-488a-84a2-3fdfd50edded">
               <id root="34667b54-e4a0-3fe6-e063-6294a90af0e1"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Children:</content>Overdosage of antihistamines, particularly in infants and children, may produce hallucinations, central nervous system depression, convulsions and death.

 </paragraph>
                  <paragraph>Antihistamines may diminish mental alertness; conversely, particularly in the young child, they may occasionally produce excitation.</paragraph>
                  <paragraph>
                     <content styleCode="bold">CNS Depressants:</content>Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Activities Requiring Mental Alertness:</content>Patients should be warned about engaging in activities requiring mental alertness and motor coordination, such as driving a car or operating machinery.

 </paragraph>
                  <paragraph>Antihistamines are more likely to cause dizziness, sedation and hypotension in elderly patients.</paragraph>
               </text>
               <effectiveTime value="20240615"/>
            </section>
         </component>
         <component>
            <section ID="La611d53e-456d-4125-9244-a94e2408f875">
               <id root="34667b54-e4a1-3fe6-e063-6294a90af0e1"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20240615"/>
               <component>
                  <section ID="L0c982e47-d0ff-4ab1-a941-aa9335a4c01e">
                     <id root="34667b54-e4a2-3fe6-e063-6294a90af0e1"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">General: </content>
                           <content styleCode="italics">Cyproheptadine has an atropine-like action and, therefore, should be used with caution in patients with</content>:

 </paragraph>
                        <paragraph>History of bronchial asthma</paragraph>
                        <paragraph>Increased intraocular pressure</paragraph>
                        <paragraph>Hyperthyroidism</paragraph>
                        <paragraph>Cardiovascular disease</paragraph>
                        <paragraph>Hypertension</paragraph>
                     </text>
                     <effectiveTime value="20240615"/>
                  </section>
               </component>
               <component>
                  <section ID="L65b01540-53da-4918-b73d-51dba4c5dd44">
                     <id root="34667b54-e4a3-3fe6-e063-6294a90af0e1"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Information for Patients:</content>Antihistamines may diminish mental alertness; conversely, particularly in the young child, they may occasionally produce excitation. Patients should be warned about engaging in activities requiring mental alertness and motor coordination, such as driving a car or operating machinery.

 </paragraph>
                     </text>
                     <effectiveTime value="20240615"/>
                  </section>
               </component>
               <component>
                  <section ID="L2648fe94-2cb7-44da-b800-dc1a2df77465">
                     <id root="34667b54-e4a4-3fe6-e063-6294a90af0e1"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Drug Interactions:</content>MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines. Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.

 </paragraph>
                     </text>
                     <effectiveTime value="20240615"/>
                  </section>
               </component>
               <component>
                  <section ID="L4c423486-ddcf-44be-9f97-7268011f2263">
                     <id root="34667b54-e4a5-3fe6-e063-6294a90af0e1"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Carcinogenesis, Mutagenesis, Impairment of Fertility:</content>Long-term carcinogenic studies have not been done with cyproheptadine. Cyproheptadine had no effect on fertility in a two-litter study in rats or a two-generation study in mice at about 10 times the human dose. Cyproheptadine did not produce chromosome damage in human lymphocytes or fibroblasts
 
  <content styleCode="italics">in vitro</content>; high doses (10
 
  <sup>-4</sup>M) were cytotoxic. Cyproheptadine did not have any mutagenic effect in the Ames microbial mutagen test; concentrations of above 500 mcg/plate inhibited bacterial growth.

 </paragraph>
                     </text>
                     <effectiveTime value="20240615"/>
                  </section>
               </component>
               <component>
                  <section ID="L3e0e0476-10aa-4f58-8bc2-f549308f7c50">
                     <id root="34667b54-e4a6-3fe6-e063-6294a90af0e1"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Pregnancy:</content>Pregnancy Category B. Reproduction studies have been performed in rabbits, mice and rats at oral or subcutaneous doses up to 32 times the maximum recommended human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to cyproheptadine. Cyproheptadine has been shown to be fetotoxic in rats when given by intraperitoneal injection in doses four times the maximum recommended human oral dose. Two studies in pregnant women, however, have not shown that cyproheptadine increases the risk of abnormalities when administered during the first, second and third trimesters of pregnancy. No teratogenic effects were observed in any of the newborns. Nevertheless, because the studies in humans cannot rule out the possibility of harm, cyproheptadine should be used during pregnancy only if clearly needed.

 </paragraph>
                     </text>
                     <effectiveTime value="20240615"/>
                  </section>
               </component>
               <component>
                  <section ID="L0c567aff-7853-4a74-bb72-c1592020286d">
                     <id root="34667b54-e4a7-3fe6-e063-6294a90af0e1"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Nursing Mothers:</content>It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from cyproheptadine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother (see
 
  <linkHtml href="#L499e964f-1f95-4c88-a041-04edd8212c5b">CONTRAINDICATIONS</linkHtml>).

 </paragraph>
                     </text>
                     <effectiveTime value="20240615"/>
                  </section>
               </component>
               <component>
                  <section ID="La8afd788-bb16-4fd8-b73f-5a461ea4c35a">
                     <id root="34667b54-e4a8-3fe6-e063-6294a90af0e1"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Pediatric Use:</content>Safety and effectiveness in pediatric patients below the age of two years have not been established. (See
 
  <linkHtml href="#L499e964f-1f95-4c88-a041-04edd8212c5b">CONTRAINDICATIONS, Newborn or Premature Infants</linkHtml>, and
 
  <linkHtml href="#Ld80fea9c-eafe-488a-84a2-3fdfd50edded">WARNINGS, Children</linkHtml>.)

 </paragraph>
                     </text>
                     <effectiveTime value="20240615"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Le5c01b28-839c-4fef-b22b-0f855834c158">
               <id root="34667b54-e4a9-3fe6-e063-6294a90af0e1"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Adverse reactions which have been reported with the use of antihistamines are as follows:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Central Nervous System:</content>Sedation and sleepiness (often transient), dizziness, disturbed coordination, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, paresthesias, neuritis, convulsions, euphoria, hallucinations, hysteria, faintness.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Integumentary:</content>Allergic manifestation of rash and edema, excessive perspiration, urticaria, photosensitivity.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Special Senses:</content>Acute labyrinthitis, blurred vision, diplopia, vertigo, tinnitus.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Cardiovascular:</content>Hypotension, palpitation, tachycardia, extrasystoles, anaphylactic shock.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Hematologic:</content>Hemolytic anemia, leukopenia, agranulocytosis, thrombocytopenia.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Digestive System:</content>Dryness of mouth, epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation, jaundice.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Genitourinary:</content>Urinary frequency, difficult urination, urinary retention, early menses.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Respiratory:</content>Dryness of nose and throat, thickening of bronchial secretions, tightness of chest and wheezing, nasal stuffiness.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Miscellaneous:</content>Fatigue, chills, headache, increased appetite/weight gain.

 </paragraph>
                  <paragraph>To report SUSPECTED ADVERSE REACTIONS, contact Quagen Pharmaceuticals LLC at 1-888-344-9603 or FDA at 1-800-FDA-1088 or www.FDA.gov/medwatch.</paragraph>
               </text>
               <effectiveTime value="20240615"/>
            </section>
         </component>
         <component>
            <section ID="L24a8b23f-b286-4742-ade2-4bd97a035b32">
               <id root="34667b54-e4aa-3fe6-e063-6294a90af0e1"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>Antihistamine overdosage reactions may vary from central nervous system depression to stimulation especially in children. Also, atropine-like signs and symptoms (dry mouth; fixed, dilated pupils; flushing, etc.) as well as gastrointestinal symptoms may occur.</paragraph>
                  <paragraph>
                     <content styleCode="italics">If vomiting has not occurred spontaneously,</content>the patient should be induced to vomit with syrup of ipecac.

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">If the patient is unable to vomit,</content>perform gastric lavage followed by activated charcoal. Isotonic or 1/2 isotonic saline is the lavage of choice. Precautions against aspiration must be taken especially in infants and children. When life-threatening CNS signs and symptoms are present, intravenous physostigmine salicylate may be considered. Dosage and frequency of administration are dependent on age, clinical response and recurrence after response. (See package circulars for physostigmine products.)

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Saline cathartics,</content>as milk of magnesia, by osmosis draw water into the bowel and, therefore, are valuable for their action in rapid dilution of bowel content.

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Stimulants</content>should
 
  <content styleCode="italics">not</content>be used. Vasopressors may be used to treat hypotension.

 </paragraph>
                  <paragraph>The oral LD
 
  <sub>50</sub>of cyproheptadine is 123 mg/kg, and 295 mg/kg in the mouse and rat, respectively.

 </paragraph>
               </text>
               <effectiveTime value="20240615"/>
            </section>
         </component>
         <component>
            <section ID="Ld9ef86ff-9b5f-48d2-a697-e693739bafe7">
               <id root="34667b54-e4ab-3fe6-e063-6294a90af0e1"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT.</paragraph>
                  <paragraph>Although intended primarily for administration to children, the syrup is also used for administration to adults who cannot swallow tablets.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Children:</content>The total daily dosage for children may be calculated on the basis of body weight or body area using approximately 0.25 mg/kg/day (0.11 mg/lb/day) or 8 mg per square meter of body surface (8 mg/m
 
  <sup>2</sup>).

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Age 2 to 6 years:</content>The usual dose is 2 mg (one teaspoonful) two or three times a day, adjusted as necessary to the size and response of the patient. The dose is not to exceed 12 mg a day.

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Age 7 to 14 years:</content>The usual dose is 4 mg (two teaspoonsful) two or three times a day, adjusted as necessary to the size and response of the patient. The dose is not to exceed 16 mg a day.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Adults:</content>The total daily dose for adults should not exceed 0.5 mg/kg/day (0.23 mg/lb/day). The therapeutic range is 4 to 20 mg a day, with the majority of patients requiring 12 to 16 mg a day. An occasional patient may require as much as 32 mg a day for adequate relief. It is suggested that dosage be initiated with 4 mg (two teaspoonsful) three times a day and adjusted according to the size and response of the patient.

 </paragraph>
               </text>
               <effectiveTime value="20240615"/>
            </section>
         </component>
         <component>
            <section ID="L78e9715b-eab9-452a-96bb-deab811b1511">
               <id root="3466a803-5be8-ab5e-e063-6394a90afa65"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Cyproheptadine Hydrochloride Oral Solution, USP, 2 mg/5 mL in a yellow, peppermint flavor vehicle, is supplied in a pint (473 mL) container.</paragraph>
                  <paragraph>(NDC 72162-2065-2)</paragraph>
                  <paragraph>(NDC 72162-2065-4).</paragraph>
                  <paragraph>Store at 20°-25°C (68°-77°F) excursion permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature].</paragraph>
                  <paragraph>Dispense in a tight, light-resistant container as defined in the USP.</paragraph>
                  <paragraph>Repackaged/Relabeled by:
  <br/>
Bryant Ranch Prepack, Inc.
  <br/>
Burbank, CA 91504
 </paragraph>
               </text>
               <effectiveTime value="20240829"/>
            </section>
         </component>
         <component>
            <section ID="La579b935-31a0-4b8c-abd8-2ebf601042b7">
               <id root="34667b54-e4ad-3fe6-e063-6294a90af0e1"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title/>
               <text>
                  <paragraph>Manufactured by: 
  <br/>
                     <content styleCode="bold">Quagen Pharmaceuticals LLC</content>
                     <br/>  West Caldwell, NJ 07006

 </paragraph>
                  <paragraph/>
                  <paragraph>52001 &amp; 52038 
  <br/>  Rev. 02/24
 </paragraph>
               </text>
               <effectiveTime value="20240615"/>
            </section>
         </component>
         <component>
            <section ID="id_link_3466aa6d-16e1-acfd-e063-6394a90a9cf4">
               <id root="3466aa6d-16e0-acfd-e063-6394a90a9cf4"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Cyproheptadine Hydrochloride Oral Solution 2 mg/5 mL</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_3466aa04-2818-a9f3-e063-6394a90afb24"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240829"/>
               <component>
                  <observationMedia ID="img_3466aa04-2818-a9f3-e063-6394a90afb24">
                     <text>Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="lbl721622065.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>